Dr. David E. Weng, MD

Dr. Weng practices at Summit Ambulatory Surgical Center, LLC in Annapolis, Maryland.

Dr. Weng's NPI, 1831154731, was assigned on April 20, 2006. Dr. Weng graduated from The Johns Hopkins University School of Medicine in 1992. Dr. Weng's Maryland license number on file is D47203.

Dr. Weng's primary practice is Summit Ambulatory Surgical Center, LLC, at 810 Bestgate Rd, Annapolis, MD 21401 in Anne Arundel County. The practice phone is (855) 405-7100.

Dr. Weng's primary practice is Summit Ambulatory Surgical Center, LLC in Annapolis, Maryland. Dr. Weng is also affiliated with Luminis Health Anne Arundel Medical Center. The medical group on file is UM Community Medical Group. Dmand AI also links Dr. Weng to 2 more hospitals, 5 medical groups and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Weng practices, 4 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Weng's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Weng is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Dr. Weng's licenses on file in 3 states: Maryland, California and Ohio.

Dmand AI lists breast cancer, chronic anemia, chronic leukemia, colorectal cancer, lung cancer, lymphoma, multiple myeloma and neutropenia among the conditions Dr. Weng treats.

CMS data shows 47,312 Medicare services from Dr. Weng across 50 procedure codes in 2024, for 659 Medicare patients. Medicare paid $1,311,072 for them. Every service was in an office.

CMS counts 659 Medicare patients who saw Dr. Weng in 2024. The largest group is 65 to 74, with 287 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 9% are also on Medicaid. Their average risk score is 1.60, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Weng's median patient age at 68, with 66% women.

In 2024, Dr. Weng wrote 1,842 Medicare Part D claims for 289 patients. 79% of them were for generic drugs. CMS names the drug for 1,443 of them, across 48 drugs with 11 or more claims each, at $3,084,622 in total drug cost. In 2023, CMS named 1,160 claims across 40 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 97 out of 100 for Dr. Weng for performance year 2024, reported individually. Dr. Weng accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Weng as offering telehealth.

Dmand AI links 17 papers to Dr. Weng, published from 2006 to 2015. 2015 was the busiest year, with 2. The most frequent topics are Breast Neoplasms, Cell Differentiation and Dendritic Cells. Dr. Weng has published most often in J Immunol. Dr. Weng's most frequent co-authors are Brian J. Czerniecki, MD, Ravi K. Amaravadi, MD and Robert M. Dean, MD.

Dmand AI links Dr. Weng to 1 clinical trial. Conditions studied include Breast Neoplasms and Breast Diseases.

CMS Open Payments shows 417 general payments to Dr. Weng from 67 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 62% of the total. Bristol-Myers Squibb Company paid the most, $4,066.

Dmand AI lists 1 award for Dr. Weng, most recently CMS Stage 1 EHR in 2014.

Dr. Weng graduated from The Johns Hopkins University School of Medicine in 1992. Dr. Weng is a member of ASCO and ASH.

Dr. Weng is in network with 20 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Elevance. Medicare plans come from the most carriers, 12. Check the plan with the practice before a visit.